KT-621 expected to start Phase 1 in the second half of 2024, with Phase 1 data in the first half of 2025 Additional KT-621 preclinical data was also featured in a poster presentation at Digestive Disease Week The company previously presented data showing its first-in-class oral STAT6 degrader, KT-621, was exquisitely selective for STAT6 over other STATs and fully blocked IL-4/IL-13 functions in key human TH2 cellular assays with picomolar potency that was superior to dupilumab. In addition, at low daily ora ...